AIMS: A suitable cut-off value for p53 overexpression and its usefulness as a prognostic factor in luminal/HER2-negative breast cancer were evaluated. PATIENTS AND METHODS: A retrospective analysis of 1,987 patients with luminal/HER2-negative breast cancer who underwent surgery between 2001 and 2009 was performed. RESULTS: p53 expression ≥50% was present in 9% of the patients. Moreover, these patients had significantly lower estrogen/progesterone receptor-positive rates, higher Ki-67 values, larger tumors, disease-positive nodes, higher nuclear grade, and shorter disease-free survival than patients with p53 expression <50% (p<0.0001). Therefore, status of p53-positive cells ≥50% was classified as p53 overexpression. These findings indicate that p53 overexpression is associated with unfavorable characteristics and prognosis. CONCLUSION: The suitable cut-off value for p53 overexpression was determined to be 50%, and p53 overexpression appears to be a significant prognostic factor in patients with luminal/HER2-negative breast cancer.
AIMS: A suitable cut-off value for p53 overexpression and its usefulness as a prognostic factor in luminal/HER2-negative breast cancer were evaluated. PATIENTS AND METHODS: A retrospective analysis of 1,987 patients with luminal/HER2-negative breast cancer who underwent surgery between 2001 and 2009 was performed. RESULTS:p53 expression ≥50% was present in 9% of the patients. Moreover, these patients had significantly lower estrogen/progesterone receptor-positive rates, higher Ki-67 values, larger tumors, disease-positive nodes, higher nuclear grade, and shorter disease-free survival than patients with p53 expression <50% (p<0.0001). Therefore, status of p53-positive cells ≥50% was classified as p53 overexpression. These findings indicate that p53 overexpression is associated with unfavorable characteristics and prognosis. CONCLUSION: The suitable cut-off value for p53 overexpression was determined to be 50%, and p53 overexpression appears to be a significant prognostic factor in patients with luminal/HER2-negative breast cancer.
Authors: Nicholas J Taylor; Nana Nikolaishvili-Feinberg; Bentley R Midkiff; Kathleen Conway; Robert C Millikan; Joseph Geradts Journal: Appl Immunohistochem Mol Morphol Date: 2016-07
Authors: Jane Ru Choi; Belinda Pingguan-Murphy; Wan Abu Bakar Wan Abas; Kar Wey Yong; Chi Tat Poon; Mat Adenan Noor Azmi; Siti Zawiah Omar; Kien Hui Chua; Feng Xu; Wan Kamarul Zaman Wan Safwani Journal: PLoS One Date: 2015-01-23 Impact factor: 3.240
Authors: Bong Kyun Kim; Se Jeong Oh; Jeong-Yoon Song; Han-Byoel Lee; Min Ho Park; Yongsik Jung; Woo-Chan Park; Jina Lee; Woo Young Sun Journal: J Breast Cancer Date: 2018-03-23 Impact factor: 3.588
Authors: Haleema Sadia; Munir Ahmad Bhinder; Asma Irshad; Beenish Zahid; Rais Ahmed; Sana Ashiq; Kausar Malik; Muhammad Riaz; Tariq Nadeem; Kanwal Ashiq; Ali Akbar Journal: Afr Health Sci Date: 2020-09 Impact factor: 0.927
Authors: Se Kyung Lee; Soo Youn Bae; Jun Ho Lee; Hyun-Chul Lee; Hawoo Yi; Won Ho Kil; Jeong Eon Lee; Seok Won Kim; Seok Jin Nam Journal: PLoS One Date: 2015-08-04 Impact factor: 3.240
Authors: Qiong Yu; Yan Li; Kun Mu; Zhishuang Li; Qingyong Meng; Xiaojuan Wu; Yan Wang; Li Li Journal: Diagn Pathol Date: 2014-03-25 Impact factor: 2.644